Tislelizumab with FOLFOX versus POF for unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, open-label Phase III comparison of two tislelizumab-containing chemotherapy combinations in patients with untreated locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with CPS≥1. Eligible adults (18–70 years) with ECOG 0–1 and adequate organ function are randomized to receive tislelizumab plus FOLFOX or tislelizumab plus POF. Treatment continues until disease progression or unacceptable toxicity, with scheduled imaging and laboratory monitoring. The trial captures tumor response, survival outcomes, and safety/adverse event data.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with advanced unresectable, histologically confirmed adenocarcinoma of the gastric or gastroesophageal junction.
* 18-70yeas.
* ECOG PS 0-1.
* No previous chemotherapy (perioperative chemotherapy, six months after fluorouracil alone or one year after oxaliplatin or a combination of taxoid and fluorouracil can be included), radiotherapy or immunotherapy.
* With normal marrow, liver and renal function: a hemoglobin (HGB) of ≥100g/L (without blood transfusion during 14 days); a leucopenia count of ≥4.0×109/L; a platelet count of ≥100×109/L; a total bilirubin (TBil) of ≤1.5 upper normal limitation (UNL); a creatinine (Cr) of ≤ 1.5 UNL; a creatinine clearance rate ≥ 50ml/min (Cockcroft-Gault); a alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT) of ≤2.5 UNL or ≤5 UNL in case of liver metastasis.
* Life expectancy ≥3 months.
* With normal electrocardiogram results and no history of congestive heart failure.
* With normal coagulation function: activated partial thromboplastin time (APTT), prothrombin time (PT) and INR, each ≤ 1.5 x ULN.
* Female subjects of child-bearing potential must agree to use contraceptive measures starting 1 week before the administration of the first dose of Tislelizumab until 8 weeks after discontinuing study drug. Male subjects must agree to use contraceptive measures during the study and 8 weeks after last dose of study drug.
* With written informed consent signed voluntarily by patients themselves or their supervisors witted by doctors.
* Have a known PD-L1 CPS/MMR (or MSI) /HER2(FISH) test result, or have sufficient samples for relevant testing.

Exclusion Criteria:

* Patients with a history of another neoplastic disease within the past three years, excluding basal cell carcinoma of the skin, cervical carcinoma in situ, or nonmetastatic prostate cancer.
* Patients with brain or central nervous system metastases, including leptomeningeal disease.
* Pregnant (positive pregnancy test) or breast feeding.
* Serious, non-healing wound, ulcer, or bone fracture.
* Significant cardiac disease as defined as: unstable angina, New York Heart Association (NYHA) grade II or greater, congestive heart failure, history of myocardial infarction within 6 months Evidence of bleeding diathesis or coagulopathy.
* History of a stroke or CVA within 6 months.
* Clinically significant peripheral vascular disease.
* HIV-positive, active hepatitis B or C (HBV, HCV);
* Inability to comply with study and/or follow-up procedures.
* Patients with any other medical condition or reason, in that investigator's opinion, makes the patient unstable to participate in a clinical trial.
* Her2-positive (IHC 3+ or 2+/FISH+) patients.

Where it's running

• Fujian cancer hospital
  Fuzhou, Fujian, China Recruiting

Study contacts

• Principal investigator: Rong bo Lin, bachelor — Fujian Cancer Hospital
• Study coordinator: Rong bo Lin, bachelor
• Email: rongbo_lin@163.com
• Phone: 13705919382

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combination treatment for advanced gastric cancer with HER2 overexpression

  This study is testing a new combination treatment for patients with advanced gastric cancer that has high levels of HER2 to see if it can improve their outcomes.

  Recruiting at 2 sites Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality and 1 other locations · NCT06560528

• Combination treatment for advanced gastric cancer with specific biomarkers

  This study is testing a new combination treatment for people with advanced gastric cancer who have certain biomarkers to see if it helps them live longer without their disease getting worse.

  Recruiting Phase 2 Nanfang Hospital, Southern Medical University · Guangzhou, Guangdong · NCT06157996

• Testing BAL0891 for advanced solid tumors and acute myeloid leukemia

  This study is testing a new treatment called BAL0891 to see if it can safely help people with advanced solid tumors or acute myeloid leukemia.

  Recruiting at 15 sites Phase 1 SillaJen, Inc. · New Haven, Connecticut and 16 other locations · NCT05768932

• Tislelizumab combined with chemoradiotherapy for advanced gastric cancer

  This study is testing if combining the immunotherapy drug Tislelizumab with chemoradiotherapy can help people with advanced stomach cancer do better before or after surgery compared to standard treatments.

  Recruiting Phase 2 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Wuhan, Hubei and 2 other locations · NCT05687357

• Evaluating a new treatment for resectable gastric cancer

  This study is testing a new combination treatment for people with early-stage gastric cancer to see if it helps shrink tumors before surgery.

  Recruiting Phase 2 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai · NCT05536102

• Tislelizumab with Tofacitinib and Docetaxel for NSCLC After First-Line Immunotherapy

  This study tests whether adding tofacitinib to tislelizumab and docetaxel helps people with locally advanced or metastatic NSCLC who did not respond to first-line immunotherapy.

  Recruiting Phase 2 Anhui Provincial Hospital · Hefei, Anhui · NCT07925866

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.